Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial

Journal of Bone Oncology

Volumn 1, Issue 2, 2012, Pages 57-62

  Lester, J E ^a   Dodwell, D ^b   BrownJ E , ^a,b   Purohit, O P ^a   Gutcher, S A ^a   Ellis, S P ^a   Thorpe, R ^a   Horsman, J M ^a,c   Coleman, R E ^a,c  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Aromatase inhibitor; Bone; Breast; Cancer; Osteoporosis

Indexed keywords

ANASTROZOLE; IBANDRONIC ACID;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84877084313     PISSN: 22121374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbo.2012.06.002     Document Type: Article

References (27)

1. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
2. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncology 2010;11: 1135-41.
3. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007;369:559-70.
4. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New England Journal of Medicine 2005;353: 2747-57. (Pubitemid 43016814)
5. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. Journal of Clinical Oncology 2007;25: 486-92. (Pubitemid 350002953)
6. Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. Journal of Clinical Oncology 2008;26(7):1051-7.
7. Mazess RB, Barden H. Bone density of the spine and femur in adult white females. Calcified Tissue International 1999;65:91-9. (Pubitemid 29350643)
8. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, et al. Effect of anastrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. Journal of Clinical Oncology 2006;24: 3629-35. (Pubitemid 46630537)
9. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmanopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncology 2007;8:119-27. (Pubitemid 46158372)
10. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncology 2008;9: 45-53.
11. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American society of clinical oncology 2003 update on the role of bispho-sphonates and bone health issues in women with breast cancer. Journal of Clinical Oncology 2003;21:4042-57. (Pubitemid 46606220)
12. Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, et al. Guidance on the managemnet of breast cancer induced bone loss: a consensus position statement from a UK expert group. Cancer Treatment Reviews 2008;34(1):S3-18.
13. Hadji P, Aapro MS, Body JJ, Brufsky A, Coleman RE, Guise T, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Annals of Oncology 2008;19:1407-16.
14. Hadji P, Aapro MS, Body JJ, Bundred NJ, Brufsky A, Coleman RE, et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance on prevention and treatment. Annals of Oncology 2011;22(12):2546-55.
15. Chesnut C, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. Journal of Bone and Mineral Research 2004;19:1241-9. (Pubitemid 41094364)
16. Liberman U, Weiss S, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. New England Journal of Medicine 1995;333: 1437-43.
17. Harris S, Watts N, Gennant H, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. Journal of the American Medical Association 1999;282:1344-52. (Pubitemid 29483192)
18. Black D, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New England Journal of Medicine 2007;356:1809-22. (Pubitemid 46698462)
19. Reginster J, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopau-sal osteoporosis: 2 year results from the mobile study. Annals of the Rheumatic Diseases 2006;65:654-61.
20. Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 2012;118: 1192-201.
21. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian breast and colorectal cancer study group. Journal of Clinical Oncology 2007;25:820-8. (Pubitemid 350002882)
22. Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. Journal of Clinical Oncology 2010;28:967-75.
23. Lester JE, Dodwell D, Purohit O, Gutcher SA, Ellis SP, Thorpe R, et al. Prevention of anastrozole-induced bone loss with oral monthly ibandronate during aromatase inhibitor therapy for breast cancer. Clinical Cancer Research 2008;14:6336-42.
24. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, et al. Efficacy of zoledronic acid in postmanopausal women with early breast cancer receiving adjuvant letrozole 36-month results of the ZO-FAST study. Annals of Oncology 2010;21:2188-94.
25. Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, et al. Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmanopausal women with early breast cancer: 12 month analysis of the EZO-FAST trial. Clinical Breast Cancer 2012;12:40-8.
26. Eastell R, Adams J, Clack G, Howell a, Cuzick J, Mackey J, et al. Long term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Annals of Oncology 2011;22:857-62.
27. Coleman RE, Banks LM, Girgis SI, Vrdoljak E, Fox J, Cawthorn SJ, et al. Reversal of skeletal effects of endocrine treatments in the intergroup exemestane study. Breast Cancer Research and Treatment 2011;124:153-61.